Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  













Fosaprepitant






●فارسی
 ●日本語
 ●Română
 ●Српски / srpski
 ●Srpskohrvatski / српскохрватски
 ●Tiếng Việt
 ●中文
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  



In other projects  


●Wikimedia Commons
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Fosaprepitant

Skeletal formula of fosaprepitant

Space-filling model of the fosaprepitant molecule

Clinical data

Trade names

Emend, Ivemend

AHFS/Drugs.com

Micromedex Detailed Consumer Information

MedlinePlus

a604003

License data

  • US DailyMed: Fosaprepitant
  • US FDA: Fosaprepitant

    • Pregnancy
    category

    • Routes of
    administration

    Intravenous

    ATC code

    Legal status

    Legal status

  • UK: POM (Prescription only)
  • US: ℞-only[4]
  • EU: Rx-only[5]

    • Pharmacokinetic data

    Bioavailability

    n/a

    Protein binding

    >95% (aprepitant)

    Metabolism

    To aprepitant

    Elimination half-life

    9 to 13 hours (aprepitant)

    Identifiers

    • [3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid

    CAS Number

    PubChem CID

    IUPHAR/BPS

    DrugBank

    ChemSpider

    UNII

    KEGG

    ChEBI

    ChEMBL

    CompTox Dashboard (EPA)

    Chemical and physical data

    Formula

    C23H22F7N4O6P

    Molar mass

    614.414 g·mol−1

    3D model (JSmol)

    • C[C@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)Cc3[nH]c(=O)n(n3)P(=O)(O)O)c4ccc(cc4)F

    • InChI=1S/C23H22F7N4O6P/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)40-20-19(13-2-4-17(24)5-3-13)33(6-7-39-20)11-18-31-21(35)34(32-18)41(36,37)38/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H,31,32,35)(H2,36,37,38)/t12-,19+,20-/m1/s1 ☒N

  • Key:BARDROPHSZEBKC-OITMNORJSA-N ☒N

    •  ☒NcheckY (what is this?)  (verify)

    Fosaprepitant, sold under the brand names Emend (US) and Ivemend (EU) among others, is an antiemetic medication,[6] administered intravenously. It is a prodrugofaprepitant.

    Fosaprepitant was developed by Merck & Co. and was approved for medical use in the United States,[7] and in the European Union in January 2008.[5]

    References[edit]

    1. ^ "Prescribing medicines in pregnancy database". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 2 March 2023. Retrieved 28 April 2023.
  • ^ "Emend IV fosaprepitant 150mg (as fosaprepitant dimeglumine) powder for injection vial (167061)". Therapeutic Goods Administration (TGA). 27 May 2022. Retrieved 28 April 2023.
  • ^ "Fosaprepitant MSN (Accelagen Pty Ltd)". Therapeutic Goods Administration (TGA). 11 November 2022. Archived from the original on 18 March 2023. Retrieved 28 April 2023.
  • ^ "Emend- fosaprepitant dimeglumine injection, powder, lyophilized, for solution". DailyMed. 2 May 2022. Archived from the original on 1 December 2021. Retrieved 27 September 2022.
  • ^ a b "Ivemend EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 31 December 2021. Retrieved 27 September 2022.
  • ^ Garnock-Jones KP (September 2016). "Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy". Drugs. 76 (14): 1365–72. doi:10.1007/s40265-016-0627-7. PMID 27510503. S2CID 30018182.
  • ^ "Drugs.com, FDA Approves Emend (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy". Archived from the original on 2008-04-09. Retrieved 2008-03-15.

    • 5-HT3 serotonin ion
    channel antagonists

  • Azasetron
  • Bemesetron
  • Cilansetron
  • Clozapine
  • Dazopride
  • Dolasetron
  • Granisetron
  • Lerisetron
  • Mianserin
  • Mirtazapine
  • Olanzapine
  • Ondansetron
  • Palonosetron (+netupitant)
  • Quetiapine
  • Ramosetron
  • Ricasetron
  • Tropisetron
  • Zatosetron

    • 5-HT serotonin G-protein
    receptor antagonists

  • Cyproheptadine
  • Hydroxyzine
  • Olanzapine
  • Risperidone
  • Ziprasidone

    • CB1 agonists
    (cannabinoids)

  • Nabilone
  • Tetrahydrocannabinol (cannabis)

    • D2/D3 antagonists

  • Haloperidol
  • Hydroxyzine
  • Metoclopramide
  • Metopimazine
  • Prochlorperazine
  • Thiethylperazine
  • Trimethobenzamide

    • H1 antagonists
    (antihistamines)

  • Dimenhydrinate
  • Diphenhydramine
  • Hydroxyzine
  • Meclizine
  • Promethazine

    • mACh antagonists
    (anticholinergics)

  • Diphenhydramine
  • Hydroxyzine (very mild)
  • Hyoscyamine
  • Scopolamine

    • NK1 antagonists

  • Fosaprepitant
  • Maropitant
  • Netupitant
  • Rolapitant

    • Others

  • Cerium oxalate
  • Dexamethasone
  • Lorazepam
  • Midazolam
  • Propofol

    • NK1

    NK2

    NK3

  • Senktide


    • Stub icon

    This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Stub icon

    This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Fosaprepitant&oldid=1190947610"
    Categories: 
    ●Antiemetics
     ●CYP3A4 inhibitors
     ●NK1 receptor antagonists
     ●Prodrugs
     ●Drugs developed by Merck & Co.
     ●Morpholines
     ●Phosphoramidates
     ●Triazoles
     ●Trifluoromethyl compounds
     ●Fluoroarenes
     ●Ethers
     ●Ureas
     ●Gastrointestinal system drug stubs
     ●Nervous system drug stubs
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Drugs with non-standard legal status
     ●Articles with changed DrugBank identifier
     ●Articles with changed ChemSpider identifier
     ●Articles with changed KEGG identifier
     ●Articles with changed EBI identifier
     ●Articles with changed InChI identifier
     ●Drug has EMA link
     ●Drugboxes which contain changes to verified fields
     ●Drugboxes which contain changes to watched fields
     ●All stub articles
      


    ●This page was last edited on 20 December 2023, at 19:49 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki